In September 2023, we hosted our International Desmoid Tumor Research Workshop in-person and virtually, and in conjunction with the DTRF Together We Will Weekend in Philadelphia, PA. Scroll down the agenda to watch the video recordings from the workshop.
Agenda
Introduction
Jeanne Whiting
Executive Director and Co-Founder, The DTRF
Welcome
Ben Alman, MD
Department Chair, Orthopedic Surgery, Duke University
Tyrosine kinase inhibitors in desmoid type fibromatosis - a Canadian multicenter retrospective CanSaRCC study
Jonathan Noujaim, MD
Assistant Clinical Professor of Medicine, Universite de Montreal (Canada)
Global consensus paper on desmoid tumor management
Bernd Kasper, MD, PhD
Professor, University of Heidelberg, Mannheim University Medical Center, Mannheim Cancer Center, Sarcoma Unit (Germany)
Studying CD47 blockade as an immunotherapy for desmoid-type fibromatosis
Gerlinde Wernig, MD
Assistant Professor, Department of Pathology, Stanford University School of Medicine
Investigating EZH2 as a druggable mediator of immune cell exclusion in desmoid tumors
Kris Vleminckx, PhD
Full Professor, Department of Biomedical Molecular Biology, Ghent University (Belgium)
Progress towards creating a prototype desmoid tumor dependency map
Jesse Boehm, PhD
Principal Investigator, Koch Institute, MIT
Gabe Augdahl
Desmoid Tumor Patient
Activation of c-JUN modulates the transcriptional activity of CD63 serving as a novel target for the treatment of desmoid type fibromatosis
Cristabelle De Souza, PhD
Postdoctoral Fellow, Cancer Biology, Stanford University
What has proteomics taught us about desmoid tumours?
Paul Huang, PhD
Head, Molecular and Systems Oncology Laboratory Division of Molecular Pathology, Institute of Cancer Research (UK)
New desmoid tumor ICD-10-CM codes
Linda Holtzman, MHA, RHIA, CCS, CCS-P, CPC, COC
President, Clarity Coding
Expression of the hexosamine biosynthesis pathway components in desmoid tumors
Joanna Przybyl, PhD
Assistant Professor, McGill University (Canada)
Treatment for upper limb desmoid causing pain and joint contracture: the importance of medication and rehabilitation
Yoshihiro Nishida, MD
Department of Rehabilitation Medicine and Orthopaedic Surgery, Nagoya University Hospital
Percutaneous Cryoablation with and without VEGF-Tyrosine Kinase Inhibitor Therapy for Pediatric and Adult Patients with Desmoid Tumors
Joseph Pressey, MD
Professor of Pediatrics, University of Cincinnati College of Medicine and Cincinnati Children’s Hospital Medical Center
A Pilot Study Evaluating the Use of Sirolimus in Children and Young Adults with Desmoid-type Fibromatosis
Aaron Weiss, DO
Associate Professor, Department of Pediatrics, Division Chief, Pediatric Hematology-Oncology, Maine Medical Center
Microbiome of desmoid tumor and its impact on the clinical course of disease
Jacob Bickels, MD
Orthopedic Oncologist, Hillel-Yaffe Medical Center
Impact of nirogacestat on pain, a key symptom in patients with desmoid tumors (DT): Results from the phase 3 DeFi study
Ravin Ratan, MD
Associate Professor, Sarcoma Medical Oncology, MD Anderson Cancer Center
Tumor volume and T2 hyperintensity changes from DeFi: a phase 3, randomized, controlled trial of nirogacestat in patients with desmoid tumors
Thierry Alcindor, MD, MSc
Senior Physician, Dana-Farber Cancer Institute/Harvard Medical School
RINGSIDE Phase 2/3 Trial of AL102 for Treatment of Desmoid Tumors (DT): Phase 2 Results
Rashmi Chugh, MD
Professor, Division of Hematology/Oncology, University of Michigan Rogel Comprehensive Cancer Center